MedTrace Logo

The Population Pharmacokinetics of Montelukast in Infants and Children

NCT03238560 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2017-08-03

No results posted yet for this study

Summary

The investigators' aim was to evaluate the population pharmacokinetics of montelukast in infants and children and define the appropriate dose in order to optimize Montelukast treatment in this vulnerable population.

Conditions

Interventions

DRUG

Montelukast Chewable Tablet

Montelukast treatment was used at a dosage of 5mg/day once daily

Sponsors & Collaborators

  • Shandong University

    lead OTHER

Principal Investigators

  • Wei Zhao, Ph.D · Shandong University

Eligibility

Min Age
1 Month
Max Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-10-01
Primary Completion
2018-06-01
Completion
2018-06-01
FDA Drug
Yes

Countries

  • China

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03238560 on ClinicalTrials.gov